Zuellig Pharma Launches Lilly's Innovative Obesity and Diabetes Medicine in Thailand
Mounjaro® (tirzepatide) will be available in the market from the end of May 2025
BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounjaro® (tirzepatide), the innovative obesity and diabetes medicine developed by Eli Lilly and Company, will be launched in Thailand at the end of May 2025. Zuellig Pharma holds the marketing authorization for Mounjaro® (tirzepatide) in Thailand, having been granted the distribution and promotion rights for the medicine by Eli Lilly and Company this year.
Mounjaro® (tirzepatide) is a once-weekly prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise; as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, in addition to other medicinal products for the treatment of diabetes; and as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
The availability of Mounjaro® (tirzepatide) is a significant advancement in the treatment of both obesity and type 2 diabetes, offering a single medication that can address both conditions through an easy-to-use prefilled pen. Mounjaro® KwikPen® (tirzepatide injection) is available in 2.5 mg, 5 mg, 7.5 mg and 10 mg, and gives healthcare providers the ability to personalize treatment plans better to meet individual patient needs.
Obesity is a critical public health concern in Thailand that affects 48% of the total population.2 The Ministry of Public Health classifies obesity as a Non-Communicable Disease (NCD) due to its strong link to rising rates for chronic illnesses, particularly type 2 diabetes. In 2024, the Department of Disease Control reported that 1 in 10 Thai individuals – a total of 6.5 million people – suffer from type 2 diabetes, impacting their physical, mental, and social well-being.2
People with diabetes face significant challenges in managing their blood sugar and preventing complications such as cardiovascular disease, chronic kidney disease, diabetic retinopathy, and diabetic foot ulcers, which can lead to severe infections and potential amputation.3
'Obesity and diabetes have gained prominence as significant health challenges in Thailand, and we are excited to accelerate the availability of Mounjaro® (tirzepatide) to patients in the region. With our deep understanding of the local regulatory landscape, as well as our proven track record of delivering innovative healthcare solutions in unmet disease areas, we are well placed to enhance the availability of the medicine in the market. This represents a significant step forward in our commitment to making healthcare more accessible, particularly in the chronic metabolic disease market,' said Rehan Saghir, Executive Vice President of Zuellig Pharma's Commercialization division.
References:
Hashtag: #ZuelligPharma #EliLillyandCompany #Diabetes #Obesity #Healthcare #Pharmaceuticals
https://www.zuelligpharma.com/
https://www.linkedin.com/company/zuellig-pharma
The issuer is solely responsible for the content of this announcement.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 17 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
For more information, visit: https://www.zuelligpharma.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Nefecon Shows IgAN Benefits Regardless of Baseline eGFR
Nefecon, an oral targeted-release formulation of budesonide that targets drug release into the distal ileum, provided significant improvements in the loss of kidney function in patients with immunoglobulin A nephropathy (IgAN) at 9 months, regardless of baseline estimated glomerular filtration rate (eGFR) status, according to a new subanalysis of the phase 3 NeflgArd study. METHODOLOGY: Patients in the NeflgArd study with primary IgAN were randomly assigned to one of two groups of 182 patients each to receive either treatment with 16 mg Nefecon or placebo daily, along with supportive care with renin-angiotensin system inhibition. This was followed by a 15-month off-drug observational period allowing for continued supportive care. For the subanalysis, the patients were further stratified on the basis of eGFR deciles in relation to the overall study population, with levels above and below 38, 43, 47, 51, 55, 60, 66, 72, and 82 mL/min/1.73 m 2 . . The median eGFR overall was 55.49 mL/min/1.73 m2 and was balanced across the Nefecon and placebo groups. TAKEAWAY: The relative benefit of Nefecon in terms of eGFR was seen across most deciles and timepoints and showed a generally greater benefit in higher baseline eGFR groups (above 72 mL/min/1.73 m 2 ). ). Furthermore, the relative urine protein-creatinine ratio benefit was observed from month 9 with Nefecon vs placebo regardless of baseline eGFR, with a continued reduction to month 12, followed by a maintained treatment benefit to month 24. The eGFR benefits with Nefecon over placebo were observed among patients within the upper and lower deciles over 2 years. eGFR showed a pronounced on-treatment benefit and a delay in decline during the observation period. IN PRACTICE: 'This NefIgArd subanalysis demonstrated that the efficacy of a 9-month Nefecon treatment course in reduction of proteinuria and preservation of kidney function was independent of baseline eGFR,' said first author Jonathan Barratt, MD, of the College of Life Sciences, University of Leicester, UK. 'So, we should be confident about treating people with Nefecon across the full range of eGFR in terms of the eGFR saving we're going to see, but also the proteinuria reduction,' he added. SOURCE: The findings were reported this week at the 62nd European Renal Association (ERA) Congress 2025. DISCLOSURES: The study was funded by Calliditas Therapeutics AB. Credit Lead image: Medscape Medscape Medical News © 2025 WebMD, LLC Cite this: Nefecon Shows IgAN Benefits Regardless of Baseline eGFR - Medscape - June 06, 2025.
Health Line
an hour ago
- Health Line
CHAMPVA and Medicare: Which Is Primary?
You can use CHAMPVA and Medicare at the same time. When you use Medicare together with CHAMPVA, Medicare is the primary payer. CHAMPVA is a cost-sharing health coverage program for some military families who don't qualify for TRICARE. You can use CHAMPVA with Medicare when you're eligible for both programs. CHAMPA will be the secondary payer to Medicare and will pay most of your out-of-pocket costs. Since there are no additional premiums if you qualify for CHAMPVA, using it alongside Medicare can significantly lower your healthcare costs. Glossary of common Medicare terms Out-of-pocket cost: This is the amount you pay for care when Medicare doesn't pay the full cost or offer coverage. It includes premiums, deductibles, coinsurance, and copayments. Premium: This is the monthly amount you pay for Medicare coverage. Deductible: This is the annual amount you must spend out of pocket before Medicare begins to cover services and treatments. Coinsurance: This is the percentage of treatment costs you're responsible for paying out of pocket. With Medicare Part B, you typically pay 20%. Copayment: This is a fixed dollar amount you pay when receiving certain treatments or services. With Medicare, this often applies to prescription medications. What is CHAMPVA? The Civilian Health and Medical Program of the Department of Veterans Affairs (CHAMPVA) is a healthcare plan for certain dependents of veterans. CHAMPVA is a different program from TRICARE, which also services military members, veterans, and their families. TRICARE eligibility is open to people who are: active or retired uniformed service members spouses or children of active or retired uniformed service members members of the Army National Guard or Reserve spouses or children of Army National Guard or Reserve members spouses or children of deceased military members certain former spouses of military members Medal of Honor recipients spouses and children of Medal of Honor recipients You can't use CHAMPVA if you have or are eligible for TRICARE. CHAMPVA helps cover certain dependents who aren't eligible for TRICARE. For example, service members who leave active duty under certain conditions might not qualify for TRICARE. However, if they have a disability caused by their service, their family may be able to enroll in CHAMPVA. How does CHAMPVA work with Medicare? Since 2001, CHAMPVA beneficiaries have been able to use their coverage after turning 65 years old. This means CHAMPVA can be used alongside Medicare. You'll need to be enrolled in Medicare to keep your CHAMPVA coverage. Here are the rules for how that works: If you turned age 65 before June 5, 2001, and did not have Medicare Part B at the time, you only need to be enrolled in Medicare Part A to keep your CHAMPVA coverage. If you turned age 65 before June 5, 2001, and were already enrolled in Part B at that time, you need to be enrolled in both Part A and Part B to keep your CHAMPVA coverage. If you turned 65 years old after June 5, 2001, you need to be enrolled in parts A and B to keep your CHAMPVA coverage. Example For example, let's say you turned 65 years old in 1999 and enrolled in Medicare parts A and B. You won't be able to drop your Part B coverage and keep your CHAMPVA coverage. However, if you turned age 65 in 1999 and enrolled in only Part A, you wouldn't need to sign up for Part B to keep your CHAMPVA coverage. You can use CHAMPVA alongside: Original Medicare (parts A and B) Medicare Advantage (Part C) Medicare Part D, which is prescription drug coverage It's important to note that CHAMPVA won't pay for the cost of your Part B premium. You should also know that you can no longer use VA healthcare facilities or healthcare professionals once you're enrolled in Medicare. What services does CHAMPVA cover? CHAMPVA is a cost-sharing health insurance program. This means it will pay a portion of the cost of health services you receive, and you'll pay the remaining amount. You won't pay a premium for CHAMPVA, but there is a $50 deductible before coverage kicks in. After you pay your deductible, CHAMPVA will pay what's known as the 'allowable amount' for all covered services. Generally, CHAMPVA will pay 75% of the allowable amount, and you'll pay the other 25%. Covered services include: hospital stays primary care doctor visits specialist visits lab work skilled nursing care home care ambulance transportation mental health services prescription drugs There are two other completely covered benefits: Hospice care from any provider is 100% covered under CHAMPVA. You can also get prescription coverage at no cost to you if you use the Department of Veterans Affairs (VA) Meds by Mail program, if you have no other prescription drug coverage. Coverage works differently if you use CHAMPVA alongside another health insurance plan, including Medicare. When you use CHAMPVA with another insurance plan, CHAMPVA becomes what's called a secondary payer. This means your other insurance plan will be billed first, and CHAMPVA will then pay the remaining cost. This can save you a lot of money on out-of-pocket medical expenses like copayments or coinsurance amounts. Who pays first for healthcare costs? Medicare is the primary payer when you use it with CHAMPVA. This means Medicare will be the first to pay the cost of any service you receive, and then CHAMPVA will pay the rest. You'll have very few out-of-pocket costs using CHAMPVA and Medicare together since CHAMPVA will generally pay any copayments or coinsurance amounts. You can expect to pay: nothing out of pocket for any service that both Medicare and CHAMPVA cover your Medicare coinsurance cost of 20% for a service Medicare covers, but CHAMPVA doesn't your CHAMPVA cost sharing of 25% for anything CHAMPVA covers, but Medicare doesn't The same rules apply to Medicare Part D. CHAMPVA will pick up your copayments on all covered prescriptions. It will also pay 75% of the cost of prescriptions that your Medicare Part D plan doesn't cover. Present both your Medicare Part D plan card and your CHAMPVA ID card at your in-network pharmacy for coverage. Getting your coverage questions answered If you're not sure who will pay for a service, you can check ahead of time by: calling Medicare's Benefits Coordination & Recovery Center at 855-798-2627 (TTY: 855-797-2627) calling CHAMPVA customer care at 800-733-8387, Monday through Friday from 8:05 a.m. to 7:30 p.m. Eastern Standard Time What about Medicare Advantage? You can use your CHAMPVA coverage with a Medicare Advantage plan. Since Medicare Advantage plans replace Original Medicare, having an Advantage plan still meets the requirement to be enrolled in Medicare to keep CHAMPVA once you're age 65. Your Medicare Advantage plan will be the primary payer, just like when you have Original Medicare. CHAMPVA will pay your copayments and other out-of-pocket costs. Your bill will go to your Medicare Advantage plan first and then to CHAMPVA. In most cases, you won't have any out-of-pocket costs. Many Medicare Advantage plans also include Part D coverage. When you use a Medicare Advantage plan that includes Part D along with CHAMPVA, your CHAMPVA benefits will pick up the cost of your prescription copayments. Medicare Advantage plans often have networks. The network includes all the providers that your Medicare Advantage plan will cover healthcare services. In many cases, you'll need to pay out of pocket for any services you receive from an out-of-network provider. However, when you use CHAMPVA along with your Medicare Advantage plan, you can often get 75% of the cost of out-of-network services covered. How do I choose the right coverage options for me? You need to enroll in Original Medicare (parts A and B) to keep your CHAMPVA coverage. You can also choose to enroll in additional Medicare parts, such as: Medicare Advantage Medigap Medicare Part D The best option for you will depend on your personal needs and budget. Medicare Advantage, Medigap, and Medicare Part D plans have their own premiums, deductibles, and other costs. CHAMPVA can cover some of these costs, but not your premiums. You might not even need additional Medicare parts if you're using CHAMPVA. For example, Medigap plans are designed to cover the out-of-pocket costs of Medicare parts A and B. However, since CHAMPVA already does this when you use it alongside Medicare, you might not need a Medigap plan. Here are some other common scenarios to consider: Original Medicare + CHAMPVA Let's say you have CHAMPVA and Medicare parts A and B, and you choose not to enroll in any other Medicare plans. You'd pay the Medicare Part B premium, and Medicare would be your primary payer for all covered services. You could get prescriptions for 25% of the allowable amount at a pharmacy or completely covered if you use the Meds by Mail program using only CHAMPVA. Original Medicare + Part D + CHAMPVA You have CHAMPVA, Medicare parts A and B, and a Part D plan. You'd pay the Medicare Part B premium and the premium for your Part D plan. Medicare would be the primary payer for services and prescriptions. CHAMPVA would pick up your copayments and coinsurance amounts. Medicare Advantage + CHAMPVA You have CHAMPVA and a Medicare Advantage plan that includes Part D coverage. You'd pay the Medicare Part B premium plus the premium for your Medicare Advantage plan. Medicare would be the primary payer for your services and prescriptions. CHAMPVA would pay your copayments and coinsurance. Ways to save on Medicare coverage It's worth noting that you may be able to find Medicare Advantage or Medigap plans in your area with $0 premiums. You can shop for plans in your area on the Medicare website and compare prices, networks, and covered services before you commit to a plan. You can also look for savings on your Medicare coverage. You might qualify for programs to help lower your costs if you have a limited income. These programs include: Extra Help, which lowers your prescription drug costs Medicare savings programs, which can lower your costs for parts A and B Ultimately, the right plan for you depends on your needs and your budget. You'll want to select a plan that includes: the doctors you want to see any prescriptions you take any services you need You can also search for premiums in your price range, and those with out-of-pocket costs you can manage. How do I know if I'm eligible for CHAMPVA? You're eligible for CHAMPVA if you're the dependent child or the current or widowed spouse of a veteran who meets one of these conditions: is permanently and totally disabled from a service-related injury or disability was permanently and totally disabled from a service-related injury or disability at the time of their death died from service-related injury or disability died during active duty is not eligible for TRICARE There is no premium cost for CHAMPVA coverage. You can apply for CHAMPVA at any time. You'll need to send in an application along with documents that prove your eligibility. Depending on your circumstances, these might include: service records marriage records birth certificates You'll also need to send in information about any other insurance plan you currently have. Your application will generally be processed in 3 to 6 weeks. If your application is approved, you will receive a CHAMPVA card in the mail. As soon as your card arrives, you can start using CHAMPVA coverage. The takeaway When you use CHAMPVA with Medicare, CHAMPVA acts as the secondary payer. CHAMPVA doesn't cover Medicare premiums but will cover most of your other out-of-pocket healthcare expenses. CHAMPVA pays 75% of the cost of most services. The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance products. Healthline Media does not transact the business of insurance in any manner and is not licensed as an insurance company or producer in any U.S. jurisdiction. Healthline Media does not recommend or endorse any third parties that may transact the business of insurance.
Medscape
an hour ago
- Medscape
Crepidiastrum Denticulatum Extract
Crepidiastrum denticulatum , a member of the Asteraceae family that is also known as Youngia denticulatum , is traditionally consumed as a vegetable in Korea. The plant is known to confer antioxidant and anti-inflammatory activity as well as protective effects. Air pollutants exact a toll on the skin, promoting the development of acne, atopic dermatitis, pigmentary changes, and wrinkles. C denticulatum is seen on skin cream labels as Pollux CD to help shield the skin against various stressors found in air pollution, including particulate matter, polycyclic aromatic hydrocarbons containing benzo[a]pyrene, heavy metals, and ultraviolet (UV) B radiation. C denticulatum is included in anti-aging skin care (and found in Zerafite Wrinkle Defense Barrier Cream) because it has been found to increase autophagy and decrease cellular senescence. This column focuses on the available evidence that supports the use of this natural extract in skin care. Leslie S. Baumann, MD Autophagy and Protection Against Skin Pollution In 2019, Yoon et al. screened numerous natural extracts to quantify their autophagy activation efficacy in cultured dermal fibroblasts, given the spate of evidence that autophagy activation can protect the skin from oxidation-induced cellular damage and signs of aging. Cells treated by C denticulatum extracts demonstrated the greatest autophagic vacuole development in the noncytotoxic range. The investigators reported that C denticulatum treatment yielded the phosphorylation of adenosine monophosphate kinase, although it did not suppress the mammalian target of rapamycin. They also assessed the anti-pollution activity of the extract using model substances, benzo[a]pyrene and cadmium chloride, with the C denticulatum extract treatment of the skin, particularly as anti-inflammatory, antipollution cosmetic agents. Anti-aging In 2020, Park et al. studied the influence of various UVB radiation levels on the development of the functional constituents of C denticulatum . They observed that none of the UVB levels (0, 0.1, 0.25, 0.5, 1.0, and 1.25 W m-2) conferred negative effects on shoot dry weight after 6 days of 6-h exposure. Shoot fresh weight was suppressed by the higher energy treatments (1.0 and 1.25 W m-2). Total carotenoid content was elevated by 0.1, 0.25, and 0.5 W m-2 energy levels. Antioxidant capacity, hydroxycinnamic acid content, and multiple sesquiterpenes were augmented on day 4 by 0.25 W m-2 treatment. The researchers determined that they had identified the potential of 0.25 W m-2 UVB to efficiently synthesize bioactive constituents of C denticulatum without suppressing growth. In a 2015 study, Kim et al. investigated the impact of various youngiaside extracts on extrinsic aging. In evaluating the molecular mechanisms of the extracts in UVB-irradiated HaCaT keratinocytes and human dermal fibroblasts, they found that the C denticulatum constituents reduced matrix metalloproteinase expression and production. Collagen expression and synthesis were also increased in human dermal fibroblasts. Furthermore, the investigators observed that the extracts significantly enhanced the antioxidant enzyme expression, thus down-regulating the reactive oxygen species generated by UVB exposure. Other notable results included decreased phosphorylation of I-kappa-B-alphaand IKK alpha/beta , suppressed nuclear factor kappa-B (NF kappa-B) p65 nuclear translocation, and robust inhibition of pro-inflammatory mediators. The investigators concluded that the tested substances found in C denticulatum have the potential to prevent and treat cutaneous aging. Animal Studies Indicate Protective Benefits In 2014, Ahn et al. found that an ethanol extract of C denticulatum significantly shielded retinal ganglion cells from eradication caused by optic nerve crush in a mouse model of glaucoma. They also determined that the primary active constituents of the herbal extract were the hydroxycinnamic acids chicoric acid and 3,5-dicaffeoylquinic acid, which have demonstrated the capacity to protect from retinal damage in multiple in vivo and in vitro studies. Later in 2014, Yoo et al. reported on the antioxidant and detoxifying activity of C denticulatum extracts. The researchers found that the botanical agent exerted hepatoprotective benefits against chronic alcohol-induced liver damage in rats. Specifically, rats treated with C denticulatum experienced substantial attenuation of fatty liver symptoms, with normalization of antioxidative capacity and lipid peroxidation of the liver. The functions of the antioxidant enzymes superoxide dismutase, catalase, glutathione reductase, and glutathione peroxidase were also restored through treatment with C denticulatum . More recently, in 2018, the oral administration of a C denticulatum extract was found to exert antioxidant and anti-inflammatory activity in improving acute renal ischemia-reperfusion injury in mice. Conclusion
